{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:35Z","timestamp":1789014575957,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12185-019-02596-z","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T05:42:52Z","timestamp":1548394972000},"page":"292-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia"],"prefix":"10.1007","volume":"109","author":[{"given":"Masatoshi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Karigane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"2596_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12185-017-2330-1","volume":"106","author":"N Usui","year":"2017","unstructured":"Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106:591\u2013611.","journal-title":"Int J Hematol"},{"key":"2596_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2596_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"2596_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"2596_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424\u201330.","journal-title":"J Clin Oncol"},{"key":"2596_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12185-017-2295-0","volume":"108","author":"D Rea","year":"2018","unstructured":"Rea D, Cayuela JM. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;108:355\u201364.","journal-title":"Int J Hematol"},{"key":"2596_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.leukres.2013.01.021","volume":"37","author":"M Breccia","year":"2013","unstructured":"Breccia M, Alimena G. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leuk Res. 2013;37:713\u201320.","journal-title":"Leuk Res"},{"key":"2596_CR8","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"2596_CR9","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","volume":"22","author":"MS Marcolino","year":"2011","unstructured":"Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22:2073\u20139.","journal-title":"Ann Oncol"},{"key":"2596_CR10","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, Nogueras-Gonz\u00e1lez GM, Burger J, Ferrajoli A, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121:3894\u2013904.","journal-title":"Cancer"},{"key":"2596_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/ajh.23879","volume":"90","author":"R Latagliata","year":"2015","unstructured":"Latagliata R, Volpicelli P, Breccia M, Vozella F, Romano A, Montagna C, et al. Incidence of persistent\/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. Am J Hematol. 2015;90:105\u20138.","journal-title":"Am J Hematol"},{"key":"2596_CR12","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"2596_CR13","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"2596_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2596_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"KDIGO CKD Work Group","year":"2013","unstructured":"KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"2596_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2596_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1253\/circj.66.987","volume":"66","author":"Examination Committee of Criteria","year":"2002","unstructured":"Examination Committee of Criteria for. \u2018Obesity Disease\u2019 in Japan; Japan Society for the Study of Obesity. New criteria for \u2018obesity disease\u2019 in Japan. Circ J. 2002;66:987\u201392.","journal-title":"Circ J"},{"key":"2596_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1291\/hypres.31.433","volume":"31","author":"E Imai","year":"2008","unstructured":"Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433\u201341.","journal-title":"Hypertens Res"},{"key":"2596_CR19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925\u201332.","journal-title":"Blood"},{"key":"2596_CR20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","volume":"23","author":"S Appel","year":"2005","unstructured":"Appel S, Balabanov S, Br\u00fcmmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23:1082\u20138.","journal-title":"Stem Cells"},{"key":"2596_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1365-2362.2006.01645.x","volume":"36","author":"H Agis","year":"2006","unstructured":"Agis H, Jaeger E, Doninger B, Sillaber C, Marosi C, Drach J, et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest. 2006;36:402\u20138.","journal-title":"Eur J Clin Invest"},{"key":"2596_CR22","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1002\/cncr.20292","volume":"100","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Quintas A, Giles F, Shan J, Rios MB, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004;100:2396\u2013402.","journal-title":"Cancer"},{"key":"2596_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/cncr.25533","volume":"117","author":"FP Santos","year":"2011","unstructured":"Santos FP, Alvarado Y, Kantarjian H, Verma D, O\u2019Brien S, Mattiuzzi G, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011;117:982\u201391.","journal-title":"Cancer"},{"key":"2596_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3949\/ccjm.83a.15065","volume":"83","author":"G Nakhoul","year":"2016","unstructured":"Nakhoul G, Simon JF. Anemia of chronic kidney disease: treat it, but not too aggressively. Cleve Clin J Med. 2016;83:613\u201324.","journal-title":"Cleve Clin J Med"},{"key":"2596_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, B\u00e1r\u00e1ny P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346\u201359.","journal-title":"Nephrol Dial Transplant"},{"key":"2596_CR26","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.V128.22.1887.1887","volume":"128","author":"E Matsuki","year":"2016","unstructured":"Matsuki E, Sakurai M, Karigane D, Kasahara H, Kikuchi T, Shimizu T, et al. Second attempt to discontinue TKI in CML patients who have sustained CMR for over 2 years is rarely successful even with the use of second generation TKIs [abstract]. Blood. 2016;128:1887.","journal-title":"Blood"},{"key":"2596_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","volume":"34","author":"A Gafter-Gvili","year":"2010","unstructured":"Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. Renal failure associated with tyrosine kinase inhibitors\u2013case report and review of the literature. Leuk Res. 2010;34:123\u20137.","journal-title":"Leuk Res"},{"key":"2596_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0002-9440(10)63651-6","volume":"163","author":"M Takikita-Suzuki","year":"2003","unstructured":"Takikita-Suzuki M, Haneda M, Sasahara M, Owada MK, Nakagawa T, Isono M, et al. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol. 2003;163:277\u201386.","journal-title":"Am J Pathol"},{"key":"2596_CR29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2174\/1871520614666140127105809","volume":"14","author":"H Fukasawa","year":"2014","unstructured":"Fukasawa H, Furuya R, Yasuda H, Yamamoto T, Hishida A, Kitagawa M. Anti-cancer agent-induced nephrotoxicity. Anticancer Agents Med Chem. 2014;14:921\u20137.","journal-title":"Anticancer Agents Med Chem"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02596-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02596-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:26:05Z","timestamp":1579825565000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02596-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2596"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02596-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SO and TM received research funding and honoraria for lectures from Bristol-Myers Squibb and Novartis Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}